about
Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndromeRecurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipientAssociation of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndromeThrombotic microangiopathy with targeted cancer agentsStructure of the N-terminal region of complement factor H and conformational implications of disease-linked sequence variationsComplement factor H and the hemolytic uremic syndromeGenetic, molecular and functional analyses of complement factor I deficiencyAntineoplastic agents and thrombotic microangiopathy.The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritisPlasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation.Atypical haemolytic uremic syndrome complicated by microangiopathic antiphospholipid-associated syndrome.Mutations in complement C3 predispose to development of atypical hemolytic uremic syndromeMutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome.Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.Thrombomodulin mutations in atypical hemolytic-uremic syndrome.Genetics and complement in atypical HUS.aHUS caused by complement dysregulation: new therapies on the horizon.Crystallographic determination of the disease-associated T1184R variant of complement regulator factor H.Endothelial cells and thrombotic microangiopathy.Assesment, treatment and prevention of atypical hemolytic uremic syndrome.Success of eculizumab in the treatment of atypical hemolytic uremic syndrome.Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome.The global aHUS registry: methodology and initial patient characteristics.Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab.Review: Complement and its regulatory proteins in kidney diseases.Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.Complement control protein factor H: the good, the bad, and the inadequate.Anti-mouse properdin TSR 5/6 monoclonal antibodies block complement alternative pathway-dependent pathogenesis.Access to the complement factor B scissile bond is facilitated by association of factor B with C3b protein.Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids.Anti-complement activity of the Ixodes scapularis salivary protein Salp20.Translational mini-review series on complement factor H: structural and functional correlations for factor H.Discrimination between host and pathogens by the complement system.Polyanion-induced self-association of complement factor H.Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations.Reincarnation of ancient links between coagulation and complement.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.Targeting mechanisms at sites of complement activation for imaging and therapy.
P2860
Q21145235-592BB994-BFAF-43F0-8572-E5A3FE8278E3Q24601710-C9B8AA36-0C7B-4E69-9BBD-69D74442419AQ24634697-4FFCB25F-663F-49F9-AAD9-D131C0431EEBQ24635904-A706BD5D-3B3F-4F7E-AADF-3A91026415A4Q24648540-59543DF2-5DB1-46A9-9BD9-73D1790E3B27Q24676234-C4A2FD01-25C6-4747-A9C5-5D86EEA7C94AQ28303343-6658B879-7544-49AF-A971-EA28BC09E0ADQ30251919-B633E1CE-90A1-4FE3-97FB-C8571A2A948FQ30377280-4AD3A724-E884-4D8C-B9B8-47BC4E2E3BBCQ30415634-BE7FDB3A-80E0-4849-8548-98C41B600014Q33379624-6FBF526A-D6B3-47C1-9F9F-E344122F985DQ33380949-2ACA2AED-523A-4F00-B16E-416FB173F806Q33381182-D6361CC2-D97C-462A-BFF7-6CE9D58E8B0AQ33384039-855ED61F-D511-49DF-AC51-8DA4C9DA5A56Q33384133-793DE9AA-4810-42A6-A584-076D63B2A773Q33385035-81976C4B-98D0-448C-B33F-31373154BA0BQ33385474-46491F64-8BCE-4207-A47D-186C06E57FAEQ33389945-3C844305-73C7-4C64-A486-6999A7589102Q33390198-68239577-0571-4AC0-BD66-8FC7611E1EFEQ33395894-03918F74-B23C-4A38-A133-0D1676E7C777Q33401369-58F64B6A-5E9B-4208-BE23-98AD44F8B8E8Q33405916-ACDC169B-6364-48D9-B16D-144AE79684F4Q33418632-154CCB68-BCAC-4C74-AF30-121E0065FC04Q33424254-E283A9E4-CEB1-4DEF-8BC3-3087A7592452Q33428291-E2D11CBB-C3B8-413F-8552-833ACE85AF07Q33439109-0BAF51A1-B6FB-42A4-A874-1AA18DD300FFQ33647738-513F9006-6255-4404-A100-2D5B16F23254Q33705135-4D1FE573-8766-4533-85F7-30CC46483B19Q34067107-0E5F01B9-09B3-482D-82D8-46A9B573CFFAQ35149952-58D7B8B2-7F97-4138-AD85-7FF606414208Q35372492-A27B99A3-1EC0-409C-B0F6-C8D599DC178CQ36187463-5B0F8170-325F-42D1-B4E0-1F4D95CC92DDQ36422019-0993B261-CC99-4E85-9F30-CB9B61263F11Q37032788-2D15ADA2-BAC8-40F4-AAB4-41D80D921D07Q37170042-E5986191-236D-4FA1-BE01-B41A8F109FE8Q37181643-D5AB02E2-48C8-4E27-A90B-33EB03D316DDQ37322141-8F66BB05-E16C-4AD8-BA1A-807B28757F61Q38543278-CCC30AF5-BEB4-4567-85BA-E77A607D6189Q42086661-3AE2C968-28D9-459C-8DBE-AC033DDCEB69Q43194836-F93FC7DA-012E-42FA-A7E0-801AD5DDCB7E
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Atypical haemolytic uraemic syndrome.
@ast
Atypical haemolytic uraemic syndrome.
@en
type
label
Atypical haemolytic uraemic syndrome.
@ast
Atypical haemolytic uraemic syndrome.
@en
prefLabel
Atypical haemolytic uraemic syndrome.
@ast
Atypical haemolytic uraemic syndrome.
@en
P356
P1476
Atypical haemolytic uraemic syndrome.
@en
P2093
Anna Richards
Timothy H J Goodship
P356
10.1093/BMB/LDL004
P577
2006-09-11T00:00:00Z